Tirzepatide: A Research Guide to the Dual GIP/GLP-1 Agonist
Tirzepatide acts on two metabolic receptors at once. A research overview of how the dual GIP/GLP-1 agonist works and what the clinical literature has examined.
What is Tirzepatide?
Tirzepatide is a synthetic peptide that activates two receptors involved in metabolism: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most earlier weight-management peptides target GLP-1 alone, which is what makes the dual mechanism a major focus of recent metabolic research.
How the Dual Mechanism Works
GLP-1 activation has been studied for slowing gastric emptying, supporting the insulin response, and reducing appetite signalling.
GIP activation is studied for its complementary role in insulin sensitivity and lipid handling.
Researchers are interested in whether engaging both pathways together produces effects greater than targeting GLP-1 on its own.
What the Clinical Literature Has Explored
- Body-weight reduction across dose ranges in controlled trials
- Markers of blood-sugar regulation and insulin sensitivity
- Appetite and food-intake signalling
- Effects on visceral fat in metabolic studies
Tirzepatide vs Other GLP-1 Peptides
Tirzepatide is frequently compared with semaglutide (a GLP-1-only agonist) and with retatrutide (a triple agonist that adds glucagon-receptor activity). Each sits at a different point on the receptor spectrum. We cover the full comparison in our retatrutide vs tirzepatide vs semaglutide article.
Availability at Peptides & You
Tirzepatide is available at Peptides & You as a lab-tested lyophilised vial, supplied with a Janoshik Certificate of Analysis. View the verified purity result at peptidesandyou.com/lab-results or see the product at peptidesandyou.com/product/tirzepatide.
For laboratory and research use only. Not for human or veterinary consumption. These statements have not been evaluated by the U.S. FDA or the Philippine FDA.